Sarepta’s DMD Gene Therapy Adcomm Likely To Focus On Dystrophin As A Surrogate Endpoint

 
• By Sue Sutter and Derrick Gingery
U turn sign
FDA reversed course and decided a panel review was needed for Sarepta's gene therapy. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies